SUTENT

In the US, SUTENT (sunitinib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Gastrointestinal Stromal Tumor, Pancreatic Cancer and Renal Cell Carcinoma.

US matches:

• Sutent

UK matches:

• SUTENT 12.5mg, 25mg, 37.5mg and 50mg Hard Capsules (SPC)

Ingredient matches for SUTENT

Sunitinib

Sunitinib is reported as an ingredient of SUTENT in the following countries:

• Poland


• Slovenia


• Spain


• Taiwan

Sunitinib malate (a derivative of Sunitinib) is reported as an ingredient of SUTENT in the following countries:

• Australia


• Austria


• Belgium


• Canada


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Finland


• France


• Germany


• Hungary


• Ireland


• Italy


• Japan


• Mexico


• Netherlands


• New Zealand


• Norway


• Slovakia


• South Africa


• Sweden


• Switzerland


• United Kingdom


• United States


• Venezuela

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.